ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD)
Epistemonikos ID: 6bacc507d1b7bad4769380c8b38294aee7a14ea0
First added on: May 21, 2024